Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System - Sorbonne Université Access content directly
Journal Articles Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring Year : 2019

Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System

Makoto Higuchi
  • Function : Author
Matej Ondrus
  • Function : Author
María Cecilia Peralta
  • Function : Author
Paola Piccini
  • Function : Author
José Ángel Pineda-Pardo
  • Function : Author
Irena Rektorová
  • Function : Author
María Rodríguez-Oroz
  • Function : Author
Axel Rominger
  • Function : Author
Klaus Seppi
  • Function : Author
A. Jon Stoessl
  • Function : Author
Alessandro Tessitore
  • Function : Author
Valtteri Kaasinen
  • Function : Author
Gregor Wenning
  • Function : Author
Hartwig R Siebner
  • Function : Author
Antonio P Strafella
  • Function : Author
James B Rowe
  • Function : Author

Abstract

Abstract Introduction Therapeutic strategies targeting protein aggregations are ready for clinical trials in atypical parkinsonian disorders. Therefore, there is an urgent need for neuroimaging biomarkers to help with the early detection of neurodegenerative processes, the early differentiation of the underlying pathology, and the objective assessment of disease progression. However, there currently is not yet a consensus in the field on how to describe utility of biomarkers for clinical trials in atypical parkinsonian disorders. Methods To promote standardized use of neuroimaging biomarkers for clinical trials, we aimed to develop a conceptual framework to characterize in more detail the kind of neuroimaging biomarkers needed in atypical parkinsonian disorders, identify the current challenges in ascribing utility of these biomarkers, and propose criteria for a system that may guide future studies. Results As a consensus outcome, we describe the main challenges in ascribing utility of neuroimaging biomarkers in atypical parkinsonian disorders, and we propose a conceptual framework that includes a graded system for the description of utility of a specific neuroimaging measure. We included separate categories for the ability to accurately identify an intention‐to‐treat patient population early in the disease (Early), to accurately detect a specific underlying pathology (Specific), and the ability to monitor disease progression (Progression). Discussion We suggest that the advancement of standardized neuroimaging in the field of atypical parkinsonian disorders will be furthered by a well‐defined reference frame for the utility of biomarkers. The proposed utility system allows a detailed and graded description of the respective strengths of neuroimaging biomarkers in the currently most relevant areas of application in clinical trials.
Fichier principal
Vignette du fichier
Alz Dem Diag Ass Dis Mo - 2019 - Eimeren - Neuroimaging biomarkers for clinical trials in atypical parkinsonian.pdf (767.5 Ko) Télécharger le fichier
Origin Files produced by the author(s)

Dates and versions

hal-04444612 , version 1 (07-02-2024)

Identifiers

Cite

Thilo van Eimeren, Angelo Antonini, Daniela Berg, Nico Bohnen, Roberto Ceravolo, et al.. Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 2019, 11 (1), pp.301-309. ⟨10.1016/j.dadm.2019.01.011⟩. ⟨hal-04444612⟩
32 View
4 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More